The effectiveness of the Pfizer vaccine, which is expected to become the first Corona 19 vaccine in Korea, has been proven around the world.
According to the industry on the 25th, the government has signed a vaccine purchase contract with individual pharmaceutical companies such as’COVAX facility’ and AstraZeneca, Janssen, Pfizer, and Modena, an international project for joint vaccine purchase and distribution. It secured 56 million people.
Among these, as Pfizer is mentioned as a vaccine that is expected to start a large-scale vaccination, interest in its effectiveness is also increasing. Earlier this month, the initial volume of Kobax is expected to arrive first, with 50,000 people.
It is known that the vaccines imported at this time are being actively reviewed as Pfizer products. If supplied through purchase contracts with individual pharmaceutical companies other than Kovacs, Pfizer products are expected to enter in the third quarter.
The timing of Pfizer vaccination through COVAX will be announced by the government through a future vaccination implementation plan.
Research results in Israel, the highest vaccination rate, continue
The effectiveness of the vaccine can be determined by checking whether antibodies against the corona 19 virus have been produced in the human body after vaccination.
The product known as Pfizer vaccine is’BNT-162b2′ jointly developed by Pfizer and Bioentech, Germany, and is an mRNA type vaccine. It is known that two vaccinations are required, and the second vaccination can raise 95% of the immunity level of the first vaccination again.
The results of experiments have been reported whether Pfizer vaccine produces antibodies in Israel, which has the highest vaccination rate in the world so far, and in the UK where a variant virus was found.
First, Israeli vaccinations began on the 20th of last month, and so far, about 30% of the population has been vaccinated. In particular, over 75% of the population over the age of 60 had been vaccinated, and it was remarkable that it had a great effect in this age group.
According to the Times of Israel report, an official from the Israeli Ministry of Health said the daily infection rate had declined to 50% 14 days after the government first launched large-scale vaccinations.
In addition, Claret, Israel’s largest health agency, reported that the probability of contracting Corona 19 decreased by 33% within 14 days of a single vaccination. In the case of Israeli medical service provider Maccabi, the infection rate fell to 60% 14 days after vaccination.
Each of these health institutions’ experimental groups is based on data of more than 400,000 patients.
However, the Israeli Ministry of Health warned that there is a possibility of spreading Corona 19 even in the results of these experiments. He stressed that even if the vaccine did not infect the human body at a positive level, it is not enough to conclude that the vaccine completely prevents the transmission of the virus because the virus in the nasal cavity can spread to others.
Report’effective’ for variants
A study by Bio&Tech that Pfizer’s vaccine is also effective against the COVID-19 strain was also announced. On the 19th, Bio&Tech published the research results on the bioarchive, a site for pre-disclosure of thesis.
Israel, which recorded the highest vaccination rate, also published various vaccination results, but was not sure whether the Pfizer vaccine would be effective against the variant Corona 19 virus.
Bio&Tech’s team reacted blood samples from 16 participants who received two doses of the Pfizer vaccine with a virus synthesized to have the same surface protein as the mutant virus. As a result, it was confirmed that the neutralizing antibody against the existing virus works the same in the mutant virus. In other words, it can be seen that the Pfizer vaccine is also effective against the variant virus.
Government prepares’ultra-low temperature refrigerator’ for Pfizer vaccination
On the 28th, the’Corona 19 Vaccination Response Promotion Team’, including the Korea Centers for Disease Control and Prevention, participated in, officially announces the plan for vaccination. The promotion team is planning to specify the priority of those who are recommended for the priority vaccination, and decide who will be the first to receive the initial volume of 50,000 Kovacs that arrives early next month.
It is also known that Pfizer Pharmaceutical is planning to apply for an item permission for the Corona 19 vaccine to the Food and Drug Administration during this month.
Related Articles
Korea Research Foundation CIO established…
US government purchases 100 million doses of Pfizer’s Corona 19 vaccine
Pfizer’s COVID-19 vaccine likely to start on the 14th
FDA Advisory Committee recommends urgent approval of Pfizer’s Corona 19 vaccine
According to the Korea Centers for Disease Control and Prevention,’SK Bioscience’ has been selected as the agency to carry out the COVID-19 vaccine distribution management system establishment and operation project, and the contract has been concluded. It will be responsible for distribution and storage of vaccines for Kovacs, AstraZeneca, Janssen and Pfizer.
Pfizer’s vaccine, an mRNA vaccine, is distributed in a’cold chain’ method that requires ultra-low temperature refrigeration. The Korea Centers for Disease Control and Prevention plans to equip and install cryogenic freezers for each vaccination center, which is an mRNA vaccination institution, to maintain the conditions for storage of the vaccine, so that vaccination can be performed without any disruption within the validity period of the vaccine.